Romidepsin Market

Romidepsin Market Size, Share & Industry Analysis, By Source (Petroleum-Based, Bio-Based), By End-User (Pharmaceuticals & Healthcare, Food & Beverage, Cosmetics & Skincare, Chemical & Polymer Industry), and Forecast Period 2025-2035

The Romidepsin market is projected to grow at a CAGR of 5.7% from 2025 to 2035, driven by increasing incidences of rare hematologic malignancies, growing clinical interest in epigenetic therapies, and expansion of oncology drug pipelines targeting T-cell lymphomas. Romidepsin is a natural product-derived histone deacetylase (HDAC) inhibitor, which induces apoptosis and cell cycle arrest by promoting acetylation of histone proteins, leading to re-expression of tumor suppressor genes.

Romidepsin is FDA-approved for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. Its role in these difficult-to-treat cancers is supported by its targeted epigenetic mechanism, intravenous dosing profile, and favorable response rates in relapsed/refractory cases. Continued research into HDAC inhibitors for broader oncology use, including solid tumors and combination regimens with immunotherapies, further enhances its strategic value.

North America dominates the market due to high diagnostic rates of rare lymphomas, strong oncology research infrastructure, and early access to orphan drug therapies. Europe shows steady adoption, supported by centralized cancer care and growing acceptance of epigenetic modulators. The Asia-Pacific region is expected to register the fastest growth, driven by increasing cancer incidence, expanding oncology trials, and rising healthcare investment. Latin America and Africa exhibit moderate growth due to improving access to specialty cancer treatments and rare disease awareness initiatives.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

Introduction

Overview of Romidepsin
Key End-Users & Industry Use Cases
Market Scope & Study Objectives

Market Overview

Global Market Size & Growth Trends (Historical & Forecast)
Demand-Supply Dynamics

Segmental Outlook

By Source
Branded Romidepsin
Generic and Biosimilar Candidates (in development)
Key End-Use Industries
Ophthalmology Clinics
Hospitals
Retail Pharmacies
Online Pharmacies

Price Analysis

Current Price Trends (Per kg & Per Ton)
Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)

Trade Analysis

Major Exporting & Importing Countries
Trade Volume & Value Statistics
Impact of Trade Regulations & Policies

Regional Analysis

North America (US and Canada)
Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
Rest of the World (Latin America, and Middle East, and Africa)

Competitive Landscape

Top Global Manufacturers & Production Capacity
Company Profiles & Key Developments
TAPI (Teva Active Pharmaceutical Ingredients) – Israel
Apicore – USA
Celgene Corporation – USA
Concord Biotech – India
MSN Laboratories – India
Sicor – Italy
Teva Pharmaceutical Industries – Israel
Viatris – USA
Zhejiang Hisun Pharmaceutical – China
Zhejiang Huida Biotech – China

Regulatory & Compliance Factors

FDA, REACH, and Other Regulatory Frameworks
Environmental & Safety Considerations
Emerging Policies Impacting Market Growth

Conclusion & Strategic Recommendations

Key Takeaways for Stakeholders
Market Entry Strategies

May 28, 2025

What is Romidepsin?

Romidepsin is a histone deacetylase (HDAC) inhibitor used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), particularly in patients who have received at least one prior systemic therapy. It works by inhibiting HDAC enzymes, which leads to the accumulation of acetylated histones and other proteins. This action results in the alteration of gene expression, cell cycle arrest, and apoptosis (programmed cell death) in cancer cells. Romidepsin is administered intravenously and is typically used when other treatments have failed, offering a targeted option for difficult-to-treat hematological malignancies. It is marketed under the brand name Istodax and is approved in several countries for specific indications within the lymphoma spectrum.

What is the market growth of Romidepsin?

The global Romidepsin market is projected to grow at a CAGR of 4.7% from 2025 to 2035, expanding from approximately USD 180 million in 2025 to about USD 290 million by 2035. This growth is driven by the rising incidence of rare hematological cancers, increasing awareness of targeted therapies, and ongoing clinical investigations exploring the broader potential of HDAC inhibitors. Although Romidepsin serves a niche market, advancements in diagnostic technologies and greater emphasis on precision oncology are expected to contribute to its steady growth, particularly as combination therapies are explored in clinical settings.

What are the drivers of the Romidepsin market?

The primary drivers of the Romidepsin market include the increasing incidence of T-cell lymphomas and the demand for effective second-line and third-line treatments. The drug's targeted mechanism of action makes it valuable for patients who do not respond to conventional chemotherapy. Additional drivers include the rise in clinical research supporting the use of HDAC inhibitors in various malignancies and the growing trend of personalized medicine. Healthcare providers and researchers are also exploring Romidepsin in combination with other agents, which may expand its use and efficacy in the coming years.

Who are the key players operating in the Romidepsin market?

The key player in the Romidepsin market is Bristol Myers Squibb, which acquired the original developer, Celgene, and markets the drug under the brand name Istodax. Other important entities include academic research institutions and biotech companies that are investigating HDAC inhibitors for expanded indications or as components of combination therapies. The relatively high cost of development and targeted patient base limits widespread competition, but biosimilar development could influence market dynamics over time.

Which region will exhibit the fastest growth in the Romidepsin market?

North America, particularly the United States, is expected to continue leading the Romidepsin market due to the high prevalence of T-cell lymphomas, robust healthcare infrastructure, and access to advanced oncology treatments. However, the Asia-Pacific region is projected to experience the fastest growth, supported by increasing cancer diagnosis rates, improving healthcare access, and growing investments in oncology research and treatment. Europe also holds a notable market share, particularly in countries with advanced medical research and reimbursement systems for orphan cancer therapies

$1800/- Single User License
$3600/- Multi User License

Experienced in market research and consulting.
Seasoned professionals with diverse industry knowledge.
Proven track record in delivering valuable insights.
Tailored methodologies for unique client needs.
End-to-end services: market analysis, competitor intelligence, consumer behavior, and strategic recommendations.
Latest tools and tech for data collection, analysis, and visualization.
Embrace of AI and machine learning for deeper insights.
Global capabilities and extensive network.
In-depth understanding of international markets, trends, and regulations.
Dedicated to addressing specific client needs and goals.
Focus on delivering value through efficient research outcomes.

How can we help you?

Reach out to discuss how our team can help your business achieve real results.

Contact Person

Mr. Anurag Tiwari

Call Us

+91-780-304-0404

Mail Us

info@omrglobal.com